Correction: Bulletin from the Extraordinary General Meeting in Dignitana AB (publ)
The press release published today on 11 January 2021 at 16:00 CET incorrectly referenced the EU Market Abuse Regulation. The reference is removed in the press release below. No other changes have been made to the previously published press release. The correction was submitted for publication on 11 January 2021, at 17:50 CET.
Bulletin from the Extraordinary General Meeting in Dignitana AB (publ)
Today, on 11 January 2021, the Extraordinary General Meeting in Dignitana AB (publ) (“Dignitana” or the “Company”) approved the Board of Directors’ resolution on a directed issue of shares made on 22 December 2020.
Resolution on a share issue with deviation from the shareholders’ pre-emption rights
On 22 December 2020, the Board of Directors of Dignitana resolved on a directed issue of 10,000,000 shares to certain strategic investors. The subscription price per share in the directed issue was set to SEK 7.50. The issue of 4,494,085 of these shares was resolved subject to a subsequent approval by an Extraordinary General Meeting. The Extraordinary General Meeting held on 11 January 2021 approved the Board of Directors’ resolution.
Through the share issue, Dignitana will raise a total of SEK 75,000,000 before issue costs.
The information was submitted for publication, through the agency of the contact person, on 11-01-2021 16:00 CET.
For further information please contact:
William Cronin, CEO
Email: bill.cronin@dignitana.com
About Dignitana
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB +46 8 121 576 90, certifiedadviser@redeye.se. Learn more at www.dignitana.se or www.dignicap.com.
Tags: